FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186320260> ?p ?o ?g. }

• W3186320260 endingPage "e002923" @default.
• W3186320260 startingPage "e002923" @default.
• W3186320260 abstract "Neuroblastoma is the most common extracranial solid tumor of childhood. Patients with high-risk disease undergo extremely aggressive therapy and nonetheless have cure rates below 50%. Treatment with the ch14.18 monoclonal antibody (dinutuximab beta), directed against the GD2 disialoganglioside, improved 5-year event-free survival in high-risk patients when administered in postconsolidation therapy and was recently implemented in standard therapy. Relapse still occurred in 57% of these patients, necessitating new therapeutic options. Bispecific trifunctional antibodies (trAbs) are IgG-like molecules directed against T cells and cancer surface antigens, redirecting T cells (via their CD3 specificity) and accessory immune cells (via their functioning Fc-fragment) toward tumor cells. We sought proof-of-concept for GD2/CD3-directed trAb efficacy against neuroblastoma.We used two GD2-specific trAbs differing only in their CD3-binding specificity: EKTOMUN (GD2/human CD3) and SUREK (GD2/mouse Cd3). This allowed trAb evaluation in human and murine experimental settings. Tumor-blind trAb and the ch14.18 antibody were used as controls. A coculture model of human peripheral blood mononuclear cells (PBMCs) and neuroblastoma cell lines was established to evaluate trAb antitumor efficacy by assessing expression of T-cell surface markers for activation, proinflammatory cytokine release and cytotoxicity assays. Characteristics of tumor-infiltrating T cells and response of neuroblastoma metastases to SUREK treatment were investigated in a syngeneic immunocompetent neuroblastoma mouse model mimicking minimal residual disease.We show that EKTOMUN treatment caused effector cell activation and release of proinflammatory cytokines in coculture with neuroblastoma cell lines. Furthermore, EKTOMUN mediated GD2-dependent cytotoxic effects in human neuroblastoma cell lines in coculture with PBMCs, irrespective of the level of target antigen expression. This effect was dependent on the presence of accessory immune cells. Treatment with SUREK reduced the intratumor Cd4/Cd8 ratio and activated tumor infiltrating T cells in vivo. In a minimal residual disease model for neuroblastoma, we demonstrated that single-agent treatment with SUREK strongly reduced or eliminated neuroblastoma metastases in vivo. SUREK as well as EKTOMUN demonstrated superior tumor control compared with the anti-GD2 antibody, ch14.18.Here we provide proof-of-concept for EKTOMUN preclinical efficacy against neuroblastoma, presenting this bispecific trAb as a promising new agent to fight neuroblastoma." @default.
• W3186320260 created "2021-08-02" @default.
• W3186320260 creator A5002512708 @default.
• W3186320260 creator A5010046497 @default.
• W3186320260 creator A5012711850 @default.
• W3186320260 creator A5018970052 @default.
• W3186320260 creator A5040803973 @default.
• W3186320260 creator A5045537384 @default.
• W3186320260 creator A5047471204 @default.
• W3186320260 creator A5056276532 @default.
• W3186320260 creator A5058019578 @default.
• W3186320260 creator A5059343286 @default.
• W3186320260 creator A5066193406 @default.
• W3186320260 creator A5066669117 @default.
• W3186320260 creator A5073296903 @default.
• W3186320260 creator A5088942486 @default.
• W3186320260 creator A5090426246 @default.
• W3186320260 date "2021-07-01" @default.
• W3186320260 modified "2023-10-01" @default.
• W3186320260 title "GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma" @default.
• W3186320260 cites W1492340933 @default.
• W3186320260 cites W1539497703 @default.
• W3186320260 cites W1755371994 @default.
• W3186320260 cites W1918654887 @default.
• W3186320260 cites W1954768511 @default.
• W3186320260 cites W1965505894 @default.
• W3186320260 cites W1972848082 @default.
• W3186320260 cites W1985837387 @default.
• W3186320260 cites W2007528004 @default.
• W3186320260 cites W2036974339 @default.
• W3186320260 cites W2040558969 @default.
• W3186320260 cites W2063960043 @default.
• W3186320260 cites W2064830862 @default.
• W3186320260 cites W2067216204 @default.
• W3186320260 cites W2068616418 @default.
• W3186320260 cites W2088282752 @default.
• W3186320260 cites W2095042482 @default.
• W3186320260 cites W2100033620 @default.
• W3186320260 cites W2116295027 @default.
• W3186320260 cites W2127478952 @default.
• W3186320260 cites W2130465135 @default.
• W3186320260 cites W2136218183 @default.
• W3186320260 cites W2137747512 @default.
• W3186320260 cites W2156330483 @default.
• W3186320260 cites W2295392443 @default.
• W3186320260 cites W2434524329 @default.
• W3186320260 cites W2575445132 @default.
• W3186320260 cites W2593919618 @default.
• W3186320260 cites W2605656134 @default.
• W3186320260 cites W2608700009 @default.
• W3186320260 cites W2611690321 @default.
• W3186320260 cites W2617103357 @default.
• W3186320260 cites W2766756296 @default.
• W3186320260 cites W2789869568 @default.
• W3186320260 cites W2889489530 @default.
• W3186320260 cites W2890612099 @default.
• W3186320260 cites W2900463817 @default.
• W3186320260 cites W2961969123 @default.
• W3186320260 cites W2993243000 @default.
• W3186320260 cites W3004101682 @default.
• W3186320260 cites W3014633285 @default.
• W3186320260 cites W3014642446 @default.
• W3186320260 cites W3017586390 @default.
• W3186320260 cites W3123833440 @default.
• W3186320260 doi "https://doi.org/10.1136/jitc-2021-002923" @default.
• W3186320260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8292814" @default.
• W3186320260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34285106" @default.
• W3186320260 hasPublicationYear "2021" @default.
• W3186320260 type Work @default.
• W3186320260 sameAs 3186320260 @default.
• W3186320260 citedByCount "9" @default.
• W3186320260 countsByYear W31863202602022 @default.
• W3186320260 countsByYear W31863202602023 @default.
• W3186320260 crossrefType "journal-article" @default.
• W3186320260 hasAuthorship W3186320260A5002512708 @default.
• W3186320260 hasAuthorship W3186320260A5010046497 @default.
• W3186320260 hasAuthorship W3186320260A5012711850 @default.
• W3186320260 hasAuthorship W3186320260A5018970052 @default.
• W3186320260 hasAuthorship W3186320260A5040803973 @default.
• W3186320260 hasAuthorship W3186320260A5045537384 @default.
• W3186320260 hasAuthorship W3186320260A5047471204 @default.
• W3186320260 hasAuthorship W3186320260A5056276532 @default.
• W3186320260 hasAuthorship W3186320260A5058019578 @default.
• W3186320260 hasAuthorship W3186320260A5059343286 @default.
• W3186320260 hasAuthorship W3186320260A5066193406 @default.
• W3186320260 hasAuthorship W3186320260A5066669117 @default.
• W3186320260 hasAuthorship W3186320260A5073296903 @default.
• W3186320260 hasAuthorship W3186320260A5088942486 @default.
• W3186320260 hasAuthorship W3186320260A5090426246 @default.
• W3186320260 hasBestOaLocation W31863202601 @default.
• W3186320260 hasConcept C147483822 @default.
• W3186320260 hasConcept C154317977 @default.
• W3186320260 hasConcept C159654299 @default.
• W3186320260 hasConcept C164027704 @default.
• W3186320260 hasConcept C202751555 @default.
• W3186320260 hasConcept C203014093 @default.
• W3186320260 hasConcept C2776090121 @default.
• W3186320260 hasConcept C2776715637 @default.

• next